KRAS G12C抑制劑的2023年研究進展

(15:45)

聽聽世界肺癌大會2023年年會說 KRAS G12C突變肺癌治療有何新的進展?

(15:20)

KRAS G12C 基因突變晚期非小細胞肺癌 治療上的新進展

(22:20)

認識治療KRAS G12C標靶藥物 Sotorasib(LUMAKRAS/洛滿舒)-1

(16:9)

KRAS G12C Inhibitors Versus Chemotherapy in Second Line - Targeted Therapies in Lung Cancer 2023

(3:56)

Molecular determinants of KRAS G12C inhibitor efficacy in advanced NSCLC

(1:59)

IBI351, a novel KRAS G12C inhibitor, in NSCLC

(1:16)

KRAS G12C inhibitors for GI cancer

(58)

Barriers to Drug Development for KRAS G12C+ NSCLC - Targeted Therapies in Lung Cancer 2023

(2:56)

ESMO highlights: KRAS G12C inhibitors

(2:9)

Overcoming resistance to KRAS G12C inhibitors in NSCLC

(1:12)

Mechanisms of resistance to KRAS G12C inhibitors

(3:17)

LY3537982: a novel KRAS G12C inhibitor in solid tumors

(1:19)

Treating KRAS G12C Mutations

(1:42)

晚期BRAF基因突變大腸直腸癌 免疫治療的未來

(18:13)

#癌症 大多數癌症來自於基因突變

(58)

晚期大腸直腸癌 迎向HER-2標靶治療新時代

(33:3)

Learning More about KRAS Lung Cancer

(2:17)

KRAS G12C Emerges as New Potential Target in Non-Small Cell Lung Cancer

(50)

Recurrent irAEs observed with sequential sotorasib after chemoimmunotherapy for KRASG12C NSCLC

(1:46)